Valoración en vida real de la eficacia y de la seguridad del cambio de dulaglutida semanal a semaglutida semanal: estudio SEMA-SWITCH

4区医学 Q3 Nursing

Endocrinologia, Diabetes y Nutricion Pub Date : 2025-06-01 DOI:10.1016/j.endinu.2025.501574

Felipe Pardo Lozano , Arantxa Rubio Marcos , Rosa Casañ Fernández , Amparo Bartual Rodrigo , Sergio Martínez-Hervás , Francisco Javier Ampudia-Blasco

{"title":"Valoración en vida real de la eficacia y de la seguridad del cambio de dulaglutida semanal a semaglutida semanal: estudio SEMA-SWITCH","authors":"Felipe Pardo Lozano , Arantxa Rubio Marcos , Rosa Casañ Fernández , Amparo Bartual Rodrigo , Sergio Martínez-Hervás , Francisco Javier Ampudia-Blasco","doi":"10.1016/j.endinu.2025.501574","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Dulaglutide and semaglutide are once-weekly administered GLP-1 receptor agonists (GLP-1 RAs) indicated for the treatment of hyperglycemia in individuals with type2 diabetes mellitus (T2DM) and obesity (BMI ≥30kg/m<sup>2</sup>).</div></div><div><h3>Objective</h3><div>To evaluate the efficacy and safety of switching from subcutaneous (SC) dulaglutide to SC semaglutide, in real-world conditions.</div></div><div><h3>Materials and methods</h3><div>A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included. This switch was motivated by insufficient reduction in glycated hemoglobin (HbA1c), the need for greater weight loss, or gastrointestinal intolerance associated with dulaglutide. Changes with semaglutide in HbA1c and weight at 6, 12, 18, and 24months, as well as any changes in associated adverse effects. Data are expressed as mean ±standard deviation.</div></div><div><h3>Results</h3><div>Previous treatment with dulaglutide (duration 16.9±13.8 months) reduced HbA1c by 0.38% (<em>P</em>   =.003 vs. baseline). After switching to semaglutide, an additional reduction in HbA1c levels was observed at 6, 12, 18, and 24months (−0.43%, <em>P</em>  =.000; −0.38%, <em>P</em>  =.622, respectively) and in weight at 6, 12, 18, and 24months (−2.7kg, <em>P</em>   =.000; −5.4kg, <em>P</em>   =.000, respectively) With no significant differences in the frequency of adverse effects after switching to semaglutide.</div></div><div><h3>Conclusions</h3><div>In real-world conditions, switching dulaglutide to semaglutide in obese patients with T2DM is associated with an additional reduction in HbA1c and weight, without notable changes in the frequency of adverse effects.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"72 6","pages":"Article 501574"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinologia, Diabetes y Nutricion","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2530016425000357","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Nursing","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Dulaglutide and semaglutide are once-weekly administered GLP-1 receptor agonists (GLP-1 RAs) indicated for the treatment of hyperglycemia in individuals with type 2 diabetes mellitus (T2DM) and obesity (BMI ≥ 30 kg/m²).

Objective

To evaluate the efficacy and safety of switching from subcutaneous (SC) dulaglutide to SC semaglutide, in real-world conditions.

Materials and methods

A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included. This switch was motivated by insufficient reduction in glycated hemoglobin (HbA1c), the need for greater weight loss, or gastrointestinal intolerance associated with dulaglutide. Changes with semaglutide in HbA1c and weight at 6, 12, 18, and 24 months, as well as any changes in associated adverse effects. Data are expressed as mean ± standard deviation.

Results

Previous treatment with dulaglutide (duration 16.9 ± 13.8 months) reduced HbA1c by 0.38% (P = .003 vs. baseline) and weight by −1.3 kg (P = .003 vs. baseline). After switching to semaglutide, an additional reduction in HbA1c levels was observed at 6, 12, 18, and 24 months (−0.43%, P = .000; −0.54%, P = .000; −0.38%, P = .021; −0.12%, P = .622, respectively) and in weight at 6, 12, 18, and 24 months (−2.7 kg, P = .000; −3.7 kg, P = .000; −5.4 kg, P = .001; −4.2 kg, P = .000, respectively) With no significant differences in the frequency of adverse effects after switching to semaglutide.

Conclusions

In real-world conditions, switching dulaglutide to semaglutide in obese patients with T2DM is associated with an additional reduction in HbA1c and weight, without notable changes in the frequency of adverse effects.

查看原文本刊更多论文

从每周杜拉谷氨酸改为每周Semaglutide的实效和安全性评估：SEMA-SWITCH研究

dulaglutide和semaglutide是每周一次的GLP-1受体激动剂（GLP-1 RAs），用于治疗2型糖尿病（T2DM）和肥胖（BMI≥30 kg/m2）患者的高血糖。目的评价在现实条件下，从皮下（SC）杜拉鲁肽转换为皮下（SC）西马鲁肽的有效性和安全性。材料和方法共纳入123例T2DM患者，无论是单药治疗还是与其他降糖药物联合使用，均改用SC semaglutide。这种转变的动机是糖化血红蛋白（HbA1c）降低不足，需要更大程度的减肥，或杜拉鲁肽相关的胃肠道不耐受。在6个月、12个月、18个月和24个月时，西马鲁肽对HbA1c和体重的变化，以及相关不良反应的任何变化。数据以平均值±标准差表示。结果既往杜拉鲁肽治疗（持续时间16.9±13.8个月）使HbA1c降低0.38% (P = 0.003)，体重降低- 1.3 kg （P = 0.003）。改用西马鲁肽后，在6、12、18和24个月观察到HbA1c水平的进一步降低(- 0.43%,P = 0.000；−0.54%,p = 0.000；−0.38%,p = 0.021；- 0.12%, P = .622)， 6、12、18和24个月时体重下降(- 2.7 kg, P = .000；−3.7 kg, P = .000；−5.4 kg, P = .001；−4.2 kg, P = .000)改用西马鲁肽后不良反应发生频率无显著差异。结论：在现实情况下，肥胖T2DM患者将杜拉鲁肽转换为西马鲁肽与HbA1c和体重的额外降低相关，而不良反应的频率没有显著变化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrinologia, Diabetes y Nutricion Nursing-Nutrition and Dietetics

CiteScore

2.10

自引率

0.00%

发文量

169

审稿时长

35 days

期刊介绍： Endocrinología, Diabetes y Nutrición is the official journal of the Spanish Society of Endocrinology and Nutrition (Sociedad Española de Endocrinología y Nutrición, SEEN) and the Spanish Society of Diabetes (Sociedad Española de Diabetes, SED), and was founded in 1954. The aim of the journal is to improve knowledge and be a useful tool in practice for clinical and laboratory specialists, trainee physicians, researchers, and nurses interested in endocrinology, diabetes, nutrition and related disciplines. It is an international journal published in Spanish (print and online) and English (online), covering different fields of endocrinology and metabolism, including diabetes, obesity, and nutrition disorders, as well as the most relevant research produced mainly in Spanish language territories. The quality of the contents is ensured by a prestigious national and international board, and by a selected panel of specialists involved in a rigorous peer review. The result is that only manuscripts containing high quality research and with utmost interest for clinicians and professionals related in the field are published. The Journal publishes Original clinical and research articles, Reviews, Special articles, Clinical Guidelines, Position Statements from both societies and Letters to the editor. Endocrinología, Diabetes y Nutrición can be found at Science Citation Index Expanded, Medline/PubMed and SCOPUS.